Enveric Biosciences, Inc.
ENVB
Rank in Stocks
#29931
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse... Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Share Price
$1.44
Last synced: 2026-11-09
Market Cap
$6.45M
Change (1 day)
1.12%
Change (1 year)
-75.76%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Enveric Biosciences, Inc. (ENVB)
Category
Healthcare
Operating Margin for Enveric Biosciences, Inc. (ENVB)
Operating Margin as of November 2026 TTM: 0.00%
According to Enveric Biosciences, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Enveric Biosciences, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | -100.00% |
| 2019 | -15.85% | -4.63% |
| 2018 | -16.62% | -32.52% |
| 2017 | -24.63% | 65.52% |
| 2016 | -14.88% | 27.07% |
| 2015 | -11.71% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | -100.00% |
| 2007 | 33.80% | -131.86% |
| 2006 | -106.10% | 1,299.74% |
| 2005 | -7.58% | -44.75% |
| 2004 | -13.72% | -64.00% |
| 2003 | -38.11% | -5,049.35% |
| 2002 | 0.77% | -103.91% |
| 2001 | -19.69% | -221.02% |
| 2000 | 16.27% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Enveric Biosciences, Inc.'s operating margin
What was Enveric Biosciences, Inc.'s operating margin in 2025?
In 2025, Enveric Biosciences, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Enveric Biosciences, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Enveric Biosciences, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2025 (0.00%).
How does Enveric Biosciences, Inc.'s operating margin compare with similar companies?
Enveric Biosciences, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.